No abstract available.
Choledochal Cyst*

Relapsing polychondritis (RP) is a rare multisystem autoimmune disease of unknown origin characterized by recurrent episodes of inflammation and progressive destruction of cartilaginous tissues. We present a patient diagnosed with meningoencephalitis associated with RP whose initial symptoms included chronic headache with memory disturbance and disorientation. After treatment of meningoencephalitis, the patient had frequent bilateral auricular swelling, polyarthralgia, and sensory neural hearing loss. Although RP is an extremely rare disease, it should be considered as a possible cause of chronic meningoencephalitis.
Arthralgia ; Autoimmune Diseases ; Headache Disorders ; Hearing Loss ; Humans ; Inflammation ; Memory ; Meningoencephalitis* ; Polychondritis, Relapsing* ; Rare Diseases

Background: As the number of large-scale studies involving multiple organizations producing data has steadily increased, an integrated system for a common interoperable format is needed. In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of global efforts are underway to develop vaccines and therapeutics. We are therefore observing an explosion in the proliferation of COVID-19 data, and interoperability is highly requested in multiple institutions participating simultaneously in COVID-19 pandemic research. Results: In this study, a laboratory information management system (LIMS) approach has been adopted to systemically manage various COVID-19 non-clinical trial data, including mortality, clinical signs, body weight, body temperature, organ weights, viral titer (viral replication and viral RNA), and multiorgan histopathology, from multiple institutions based on a web interface. The main aim of the implemented system is to integrate, standardize, and organize data collected from laboratories in multiple institutes for COVID-19 non-clinical efficacy testings. Six animal biosafety level 3 institutions proved the feasibility of our system. Substantial benefits were shown by maximizing collaborative high-quality non-clinical research. Conclusions This LIMS platform can be used for future outbreaks, leading to accelerated medical product development through the systematic management of extensive data from non-clinical animal studies.